IMMUNOSCORE® Clinical Research (CR)
IMMUNOSCORE®CR includes several assays which combine immunohistochemistry (up to 7 biomarkers on a single FFPE slide), sophisticated algorithms and advanced image analysis.
IMMUNOSCORE®CR TL
IMMUNOSCORE®CR TL (T lymphocytes) accurately quantifies T cell infiltrate, in and around the tumor, in a variety of cancer types to distinguish between cold, altered, and hot tumors.
Developed and adapted from the algorithm of the IMMUNOSCORE ® IVD test for localized Colon Cancer, IMMUNOSCORE®CR TL measures the density of CD8+ & CD3+ T cells of resected or biopsied cancer samples.
Posters on IMMUNOSCORE®CR TL
Poster presented at SITC2019 annual meetingTumor Infiltrating Lymphocytes (TILs) in triple-negative breast cancer: High Immunoscore is associated with pathological CR in patients receiving neoadjuvant chemotherapy. BL Rapoport, The Medical Oncology Centre of Rosebank, Johannnesburg, South Africa
Poster presented at ESMO 2019 annual meeting High Immunoscore® is associated with good response to neo-adjuvant chemotherapy and prolonged survival in advanced Head and Neck cancer patients. Haitham Mirghani, Department of head and neck oncology, Gustave Roussy Cancer Center
Poster presented by Transgene at ESMO2019 annual meeting In this study, HalioDx Immunoscore®, Immunosign® and others clinical research service have been performed to assess Immune contexture of patients. The treatment is associated with changes in tumor microenvironment that are likely to change the course of the pathology by shifting tumor from a cold state to a hotter immune status even in heavily pretreated patients. This may be particularly useful in patient with “immune-excluded” tumor phenotype as shown on the individual study case.
IMMUNOSCORE®CR IC
IMMUNOSCORE®CR IC (Immune checkpoint) allows on a single slide, the precise quantification of positive CD8+ cells and whole PD-L1+ cells (cells/mm²) but also cells clustering and proximity index to predict the response to IC modulation.
IMMUNOSCORE® IC is available as a CE-IVD test for Non-Small Cell Lung Cancer (NSCLC).
Poster on IMMUNOSCORE®CR IC
- Poster presented by Transgene at ESMO2019 annual meeting In this study, HalioDx Immunoscore®, Immunosign® and others clinical research service have been performed to assess Immune contexture of patients. The treatment is associated with changes in tumor microenvironment that are likely to change the course of the pathology by shifting tumor from a cold state to a hotter immune status even in heavily pretreated patients. This may be particularly useful in patient with “immune-excluded” tumor phenotype as shown on the individual study case.
IMMUNOSCORE®CR TCE
IMMUNOSCORE®CR TCE (T cell exhaustion) is based on IHC multiplex technology (Brightplex®), an automated workflow that takes advantage of brightfield microscopy to accurately analyze up to 7 biomarkers simultaneously on a single slide and identify complex immune cells phenotypes. Basically, specific immune cell populations can be precisely quantified and spatially localized in specific region of interest of the tissue (tumor, invasive margin, stroma, parenchyma).
More info on Brightplex® technology here
IMMUNOSCORE® CR SC
This range of tests includes panel of biomarkers for a precise identification of Suppressor Cells (SC) within the tumor microenvironment (TME).
IMMUNOSCORE MDSC identifies accurately subgroups of myeloid derived suppressive cells by phenotyping them using 7 different biomarkers. IMMUNOSCORE T Reg is based on the detection of CD4 and FOXP3 and allows to identify the Treg population into the tumor microenvironment.
Other indications on existing panels or additional panels can be available on demand.
More info on Brightplex® technology here
Publications
Galon J and Bruni D
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
Nat Rev Drug Discov. 2019
18(3):197-218
More infoAngelova M et al.
Evolution of Metastases in Space and Time under Immune Selection
Cell. 2018
175(3):751-765.e16
More infoPagès et al.
International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study
The Lancet, 2018
May 10, 2018
More infoMlecnik B et al.
Comprehensive Intrametastatic Immune Quantification and Major Impact of Immunoscore on Survival.
J Natl Cancer Inst. 2018 ;
Jan 1;110(1). doi: 10.1093
More infoBerghoff AS et al.
Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases.
Oncoimmunology 2016 ;
Jun 9;5(1):e1057388
More infoKirilovsky A et al.
Rational bases for the use of the Immunoscore in routine clinical settings as a prognostic and predictive biomarker in cancer patients
Int Immunol. 2016
doi: 10.1093/intimm/dxw021
More infoHermitte F
Biomarkers immune monitoring technology primer: Immunoscore® Colon
Journal for ImmunoTherapy of Cancer 2016
DOI: 10.1186/s40425-016-0161-x
More infoGalon J et al
Validation of the Immunoscore (IM) as a prognostic marker in stage I/II/III colon cancer: Results of a worldwide consortium-based analysis of 1,336 patients.
2016 ASCO Annual Meeting
J Clin Oncol 34, 2016 (suppl; abstr 3500)
More infoMlecnik B et al.
Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability.
Immunity. 2016 ;
Mar 15;44(3):698-711.
More infoMlecnik B et al.
The tumor microenvironment and Immunoscore are critical determinants of dissemination to distant metastasis.
Sci Transl Med. 2016 ;
24 Feb 2016, Vol. 8, Issue 327, pp. 327ra26.
More infoGalon J et al.
Towards the introduction of the 'Immunoscore' in the classification of malignant tumours
J Pathol. 2014
Jan;232(2):199-209.
More infoGalon J et al.
Cancer classification using the Immunoscore: a worldwide task force.
J Transl Med 2012 ;
10 : 205.
More infoMlecnik B et al.
Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction.
J Clin Oncol 2011 ;
29 : 610-8.
More infoPagès F al.
In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer.
J Clin Oncol 2009 ;
27 : 5944-51.
More infoGalon J et al.
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome.
Science 2006 ;
313 : 1960-4.
More infoInterested in Immunoscore® CR ? Contact us
- Pharma Services
- Immunogram
- Our offer within the TME
- Immunoscore® CR
- Brightplex®
- Immunosign®
- IO Sequencing
- Biostats
- On demand Assays
- The Cancer Immune Atlas
